[3]Ying Cheng , et al. Anlotinib plus Etoposide/Carboplatin (EC) versus Placebo plus EC in First-line Therapy for Extensive-stage Small Cell Lung Cancer (ES-SCLC): A Randomized, Double-blind, Parallel controlled, Phase...
70.84% were stage IV. These patients showed a median OS (mOS) of 6mo (5.83-6.17). 45.37% of them had liver metastasis (mets), bone: 33.41%, brain: 23.86%, lung: 19.47% and other mets sites: 16.88%. Median OS in patients with liver mets, bone, brain and lung were 4 (3.79-...
(5) 斯鲁利单抗+化疗可能更适合年轻患者(年龄< 65 岁), 而阿替利珠单抗+化疗更适合老年患者(年龄≥65 岁)。 参考文献 1. Wang S, Li Y, Liu Z, et al. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network...
“小细胞肺癌(smallcelllungcancer, SCLC)占所有肺癌病例的大约15%,1973年美国退伍军人医院分期系统将SCLC分为局限期(Limited stage, LS)和广泛期(Extensive stage, ES),局限期定义为肿瘤局限于一侧胸腔、同侧肺门、双侧纵隔、同侧锁骨上区,且除外恶性心包积液或恶性...
[4]Gao, Xinyu et al. “The therapeutic effect of radiotherapy combined with systemic therapy compared to radiotherapy alone in patients with simple brain metastasis after first-line treatment of limited-stage small cell lung cancer: a retrospective study.” World journal of surgical oncology vol. ...
[4]Ying Cheng. 2023 ESMO IO. #84P [5]Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630...
8.Ying Cheng, et al. EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). 2023 ESMO Abstract LBA93. ...
4. Paz-Ares LG, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408. doi:10.1016/j.esmoop.2022.100408 ...
27、tine for the treatment of recurrent small-cell lung cancer.J Chin Oncol.1999;17:658-667.,Topotecan单药治疗证实可以明显改善+四项重要疾病相关症状:呼吸困难、疲劳、声音嘶哑和日常活动受限1,67,血液学毒性 70%的Topotecan组患者发生了4度中性粒细胞减少,而CAV组患者的发生率为72% 非血液学毒性 两组发...
4.Putora PM, Glatzer M, Belderbos J, et al. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol. 2019;133:163-166. 5.Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II ra...